INTRODUCTION: Stereotactic body radiation therapy (SBRT) is being increasingly applied in the treatment of @entity1149 ( @entity1149 ) because of its high local efficacy. This study aims to examine survival outcomes in elderly @entity1 with inoperable stage I @entity1149 treated with SBRT. METHODS: A total of 31 @entity1 with single lesions treated with fractionated SBRT from 2008 to 2011 were retrospectively analyzed. A median prescribed dose of 48 Gy was delivered to the prescription isodose line, over a median of four treatments. The median @entity10204 ( @entity10204 ) was 105.6 (range 37.50-180), and the median age was 73 (65-90 years). No @entity1 received concurrent chemotherapy. RESULTS: With a median follow up of 13 months (range, 4-40 months), the actuarial median @entity1349 ( @entity1349 ) and progression-free survival (PFS) were 32 months, and 19 months, respectively. The actuarial median local control (LC) time was not reached. The survival outcomes at median follow up of 13 months were 80%, 68%, and 70% for LC, PFS, and @entity1349 , respectively. Univariate analysis revealed a @entity10204 of >100 Gy was associated with improved LC rates (P = 0.02), while squamous cell histology predicted for worse LC outcome at median follow up time of 13 months (P = 0.04). Increased @entity5 volume was a worse prognostic indicator of both LC and @entity1349 outcomes (P < 0.05). Finally, female gender was a better prognostic factor for @entity1349 than male gender (P = 0.006). There were no prognostic indicators of PFS that reached statistical significance. No acute or subacute high-grade @entity137 were documented. CONCLUSION: SBRT is a safe, feasible, and effective treatment option for elderly @entity1 with inoperable early stage @entity1149 . @entity10204 , histology, and @entity5 size are predictors of local control, while @entity5 size and gender predict @entity1349 .

Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity10204 :: ('MESH:D021081', 'Disease') :: ['biologically effective dose', 'BED'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
